ST6GALNAC5 Human
Sf9, Baculovirus cells.
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5, GD1 alpha synthase, GalNAc alpha-2,6-sialyltransferase V, ST6GalNAc V, ST6GalNAcV, Sialyltransferase 7E, SIAT7-E, SIAT7E
Greater than 90.0% as determined by SDS-PAGE.
Description
ST6GALNAC5 produced in Sf9 Baculovirus cells is a single, glycosylated polypeptide chain containing 316 amino acids (30-336a.a.) and having a molecular mass of 36.4kDa.
ST6GALNAC5 is expressed with a 6 amino acid His tag at C-Terminus and purified by proprietary chromatographic techniques.
Product Specs
The enzyme ST6GALNAC5, also known as alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5, belongs to the glycosyltransferase 29 protein family. It plays a role in the biosynthesis of ganglioside GD1a by transferring sialic acid. As part of the protein glycosylation process, ST6GALNAC5 modifies proteins. Notably, it is specifically found in brain tissue and has been linked to breast cancer cell metastasis to the brain, potentially by facilitating the crossing of the blood-brain barrier.
Produced using Sf9 insect cells, ST6GALNAC5 is a single, glycosylated polypeptide chain with a molecular weight of 36.4 kDa. It encompasses amino acids 30 to 336 and includes a 6-amino acid His tag located at the C-terminus. Purification is achieved through proprietary chromatographic methods.
This ST6GALNAC5 protein solution has a concentration of 0.25 mg/ml and is supplied in a buffer consisting of Phosphate Buffered Saline (pH 7.4) with 10% glycerol.
For short-term storage (up to 2-4 weeks), the solution can be kept at 4°C. For longer periods, it is recommended to store the solution at -20°C. Adding a carrier protein such as HSA or BSA (0.1%) is advisable for long-term storage to maintain protein stability. Repeated freeze-thaw cycles should be avoided.
The purity of ST6GALNAC5 is determined by SDS-PAGE analysis and exceeds 90%.
Alpha-N-acetylgalactosaminide alpha-2,6-sialyltransferase 5, GD1 alpha synthase, GalNAc alpha-2,6-sialyltransferase V, ST6GalNAc V, ST6GalNAcV, Sialyltransferase 7E, SIAT7-E, SIAT7E
Sf9, Baculovirus cells.
ADLGGQKERP PQQQQQQQQQ QQQASATGSS QPAAESSTQQ RPGVPAGPRP LDGYLGVADH KPLKMHCRDC ALVTSSGHLL HSRQGSQIDQ TECVIRMNDA PTRGYGRDVG NRTSLRVIAH SSIQRILRNR HDLLNVSQGT VFIFWGPSSY MRRDGKGQVY NNLHLLSQVL PRLKAFMITR HKMLQFDELF KQETGKDRKI SNTWLSTGWF TMTIALELCD RINVYGMVPP DFCRDPNHPS VPYHYYEPFG PDECTMYLSH ERGRKGSHHR FITEKRVFKN WARTFNIHFF QPDWKPESLA INHPENKPVF HHHHHH
Product Science Overview
ST6GALNAC5 catalyzes the biosynthesis of ganglioside GD1alpha from GM1b in the brain by transferring the sialyl group (N-acetyl-alpha-neuraminyl or NeuAc) from CMP-NeuAc to the GalNAc residue on the NeuAc-alpha-2,3-Gal-beta-1,3-GalNAc sequence of GM1b . This process is essential for the proper functioning of neural cells and has implications in various neurological processes.
Recent studies have highlighted the role of ST6GALNAC5 in cancer progression, particularly in prostate cancer (PCa) and breast cancer:
- Prostate Cancer: ST6GALNAC5 has been identified as an adverse prognostic biomarker in metastatic prostate cancer. Its overexpression is associated with higher Gleason scores and poor prognosis in PCa patients. The transcription factor GATA2 has been found to upregulate ST6GALNAC5, promoting cancer cell invasion .
- Breast Cancer: ST6GALNAC5 is implicated in the metastasis of breast cancer cells to the brain. It potentially enables cancer cells to cross the blood-brain barrier, facilitating the spread of cancer to the brain .
The aberrant expression of ST6GALNAC5 in various cancers makes it a potential target for therapeutic interventions. Understanding its role in cancer progression can lead to the development of novel treatments aimed at inhibiting its function and preventing metastasis.
